Status:
NOT_YET_RECRUITING
The Effect of Glucagon on Cerebral Glucose Metabolism in Healthy Humans
Lead Sponsor:
Nicolai Jacob Wewer Albrechtsen
Collaborating Sponsors:
Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital - Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark
Conditions:
Cerebral Glucose Metabolism
Eligibility:
All Genders
55-70 years
Phase:
NA
Brief Summary
This is a pilot study in which the investigators will investigate the effect of exogenous glucagon on cerebral glucose metabolism in healthy humans. Participants will participate in either part C or ...
Detailed Description
Participants in this study will participate in four visits; one screening visit and three study days. Participants will be instructed to avoid strenuous exercise and alcohol intake two days prior to ...
Eligibility Criteria
Inclusion
- Age 55 to 70 years
- BMI under or equal to 30 kg/m2
- Capable of understanding the participant information and signing the consent form
Exclusion
- Enrolment in other research projects that might interfere with the study
- Diabetes diagnosis (type 1 and 2)
- Use of medications which, in the opinion of the investigator, may jeopardise participant's safety or compliance with the protocol
- Diagnosis of psychiatric disorders, dementias, or any other neurological disorders that in the opinion of the investigator precludes compliance with the study protocol, evaluation of the results or represents an unacceptable risk for the participants safety
- Severe claustrophobia
- Impaired liver og kidney function
- Cardiac problems including any of the following:
- Classified as being in New York Heart Association (NYHA) class III or IV
- Angina pectoris (chest pain) within the last 6 months
- Acute myocardial infarction (heart attack) within last 2 years
- Inadequately treated blood pressure at screening defined as repeated resting blood pressure outside the range 90-150 mmHg for systolic and 50-100 mmHg for diastolic.
- Active or recent malignant disease
- Current or history of severe alcohol use or drug/chemical abuse as per investigator's judgement
- Any chronic disorders or severe diseases which, in the opinion of the investigator, might jeopardise participant's safety or compliance with the protocol
Key Trial Info
Start Date :
March 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2026
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT06877208
Start Date
March 1 2025
End Date
March 1 2026
Last Update
March 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital - Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark
Copenhagen, Denmark, 2400